Full-Time

Executive Director – Lead Epidemiologist

Respiratory Vaccines and COVID-19

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • PhD in Epidemiology is preferred; related field and equivalent relevant experience will be considered.
  • ≥10 years’ experience in an industry setting, preferably in vaccines or a related therapeutic area. Preference given to candidates with previous experience in vaccine development, infectious diseases, and particularly COVID or other respiratory viruses.
  • ≥3 years of experience in a supervisory role.
  • Proficiency in epidemiological study design, data analysis, and use of large electronic healthcare databases (e.g., EHR, administrative/claims data).
  • Creative problem-solver with the ability to thrive in a fast-paced environment.
  • Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals.
  • Excellent analytical, problem-solving, and strategic planning skills.
  • Strong interpersonal skills commensurate with the need to work closely with CROs, investigators, consultants, and Moderna team members across functions in a matrix environment.
  • Exceptional written and oral communication skills to meet the needs of varied audiences.
  • Integrated understanding of global regulatory authorities, ICH GCP, and GPP/GEP guidelines; prior interaction with major regulators and public health agencies is preferred.
Responsibilities
  • Accountable for the leadership, development, and execution of the Epidemiology strategy for COVID (product and team lead).
  • Accountable for general oversight and coordination of the Moderna respiratory virus portfolio.
  • Provide epidemiologic input to the product development, pre-clinical, clinical, safety, and regulatory affairs teams, contributing to the integrated evidence plans for COVID and respiratory vaccines.
  • Support the design and execution of pre- and post-marketing epidemiology plans, including burden of disease studies, literature reviews and gap analyses, mathematical modeling, and post-marketing safety, effectiveness, and impact studies, as needed.
  • Set the scientific direction and develop protocols, data analysis plans, study reports and peer-reviewed publications to support COVID and respiratory vaccines.
  • Actively contribute to the development of Target Product Profiles, particularly in terms of demonstrating burden of disease/unmet medical need and shaping post-licensure plans.
  • Serve as a key partner with Medical Affairs, Commercial, and HEOR teams in terms of market-shaping activities, including collaboration on health economic models.
  • Develop collaborations with external experts and investigators to facilitate epidemiologic data generation activities.
  • Provide epidemiologic support to other Moderna vaccine programs as needed.
  • Develop and maintain strong, collaborative relationships with the broader Moderna organization.
  • Work closely with cross-functional teams, including clinical development, biostatistics, regulatory affairs, and external partners, to ensure alignment and integration of epidemiological data into the vaccine development program.
  • Analyze epidemiological data to generate insights on disease burden, transmission dynamics, and vaccine impact. Utilize methodologies to ensure robust data analysis.
  • Present findings to a diverse audience of internal and external stakeholders.
  • Lead or contribute to epidemiology content for regulatory submission documents; interact with regulatory agencies and other external authorities as needed.
  • Contribute to epidemiologic knowledge of COVID and other respiratory viruses in the external environment via abstracts, manuscripts, and presentations at academic conferences.
  • Contribute to the culture of quality and methodologic rigor in the design and execution of epidemiologic activities to the highest standard of quality and compliance.
  • Oversee direct reports.
  • Provide mentorship and guidance to junior epidemiologists and other team members, fostering a collaborative and innovative team environment.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?